{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:58:00Z","timestamp":1790686680027,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:00:00Z","timestamp":1788048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:00:00Z","timestamp":1788048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014941","name":"Cytokinetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014941","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40262-026-01694-6","type":"journal-article","created":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T17:06:18Z","timestamp":1788109578000},"page":"1575-1589","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A First-in-Human Study of Ulacamten, a Novel Cardiac Myosin Inhibitor for HFpEF"],"prefix":"10.1007","volume":"65","clinical-trial-number":[{"clinical-trial-number":"nct05877053","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9353-9139","authenticated-orcid":false,"given":"Justin D.","family":"Lutz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7512-1737","authenticated-orcid":false,"given":"Neha","family":"Maharao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyrell","family":"Simkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Cheplo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genzhou","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camelia","family":"Dumitrescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"Griffith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajaa","family":"Sukhun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Heitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Kupfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polina","family":"German","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,30]]},"reference":[{"issue":"9","key":"1694_CR1","first-page":"582","volume":"96","author":"JD Gazewood","year":"2017","unstructured":"Gazewood JD, Turner PL. Heart failure with preserved ejection fraction: diagnosis and management. Am Fam Physician. 2017;96(9):582\u20138.","journal-title":"Am Fam Physician"},{"issue":"1 Pt 2","key":"1694_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jcmg.2018.12.034","volume":"13","author":"M Obokata","year":"2020","unstructured":"Obokata M, Reddy YNV, Borlaug BA. Diastolic dysfunction and heart failure with preserved ejection fraction: understanding mechanisms by using noninvasive methods. JACC Cardiovasc Imaging. 2020;13(1 Pt 2):245\u201357.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"18","key":"1694_CR3","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1093\/cvr\/cvac133","volume":"118","author":"NR Pugliese","year":"2023","unstructured":"Pugliese NR, Pellicori P, Filidei F, De Biase N, Maffia P, Guzik TJ, et al. Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions. Cardiovasc Res. 2023;118(18):3536\u201355.","journal-title":"Cardiovasc Res"},{"issue":"10431","key":"1694_CR4","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0140-6736(23)02756-3","volume":"403","author":"P Campbell","year":"2024","unstructured":"Campbell P, Rutten FH, Lee MM, Hawkins NM, Petrie MC. Heart failure with preserved ejection fraction: everything the clinician needs to know. Lancet. 2024;403(10431):1083\u201392.","journal-title":"Lancet"},{"issue":"11","key":"1694_CR5","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1161\/CIRCRESAHA.119.313572","volume":"124","author":"MA Pfeffer","year":"2019","unstructured":"Pfeffer MA, Shah AM, Borlaug BA. Heart failure with preserved ejection fraction in perspective. Circ Res. 2019;124(11):1598\u2013617.","journal-title":"Circ Res"},{"key":"1694_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2019.00638","volume":"10","author":"AB Gevaert","year":"2019","unstructured":"Gevaert AB, Boen JRA, Segers VF, Van Craenenbroeck EM. Heart failure with preserved ejection fraction: a review of cardiac and noncardiac pathophysiology. Front Physiol. 2019;10:638.","journal-title":"Front Physiol"},{"issue":"3","key":"1694_CR7","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s10741-024-10385-y","volume":"29","author":"N Desai","year":"2024","unstructured":"Desai N, Olewinska E, Famulska A, Remuzat C, Francois C, Folkerts K. Heart failure with mildly reduced and preserved ejection fraction: a review of disease burden and remaining unmet medical needs within a new treatment landscape. Heart Fail Rev. 2024;29(3):631\u201362.","journal-title":"Heart Fail Rev"},{"issue":"4","key":"1694_CR8","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/s00059-022-05124-8","volume":"47","author":"FR Heinzel","year":"2022","unstructured":"Heinzel FR, Shah SJ. The future of heart failure with preserved ejection fraction: deep phenotyping for targeted therapeutics. Herz. 2022;47(4):308\u201323.","journal-title":"Herz"},{"issue":"1","key":"1694_CR9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cardfail.2024.07.001","volume":"31","author":"B Bozkurt","year":"2024","unstructured":"Bozkurt B, Ahmad T, Alexander K, Baker WL, Bosak K, Breathett K, et al. HF STATS 2024: Heart failure epidemiology and outcomes statistics an updated 2024 report from the Heart Failure Society of America. J Card Fail. 2024;31(1):66\u2013116.","journal-title":"J Card Fail"},{"issue":"10","key":"1694_CR10","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1161\/CIRCRESAHA.121.318172","volume":"128","author":"VL Roger","year":"2021","unstructured":"Roger VL. Epidemiology of heart failure: a contemporary perspective. Circ Res. 2021;128(10):1421\u201334.","journal-title":"Circ Res"},{"issue":"2","key":"1694_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25020794","volume":"25","author":"L Stoicescu","year":"2024","unstructured":"Stoicescu L, Cri\u015fan D, Morgovan C, Avram L, Ghibu S. Heart failure with preserved ejection fraction: the pathophysiological mechanisms behind the clinical phenotypes and the therapeutic approach. Int J Mol Sci. 2024;25(2):794.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1694_CR12","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s10741-018-9714-z","volume":"23","author":"B Upadhya","year":"2018","unstructured":"Upadhya B, Haykowsky MJ, Kitzman DW. Therapy for heart failure with preserved ejection fraction: current status, unique challenges, and future directions. Heart Fail Rev. 2018;23(5):609\u201329.","journal-title":"Heart Fail Rev"},{"issue":"1","key":"1694_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","volume":"134","author":"SJ Shah","year":"2016","unstructured":"Shah SJ, Kitzman DW, Borlaug BA, Van Heerebeek L, Zile MR, Kass DA, et al. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation. 2016;134(1):73\u201390.","journal-title":"Circulation"},{"issue":"7","key":"1694_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13071619","volume":"13","author":"H Savsin","year":"2025","unstructured":"Savsin H, Tokarek T. Comprehensive review: mavacamten and aficamten in hypertrophic cardiomyopathy. Biomedicines. 2025;13(7):1619.","journal-title":"Biomedicines"},{"key":"1694_CR15","unstructured":"Sarkar SS, Hartman JJ, Hwee DT, Chuang C, Cremin P, deRosier A, et al. Preclinical characterization of CK-4021586, a new class of cardiac myosin inhibitors for the treatment of hypertrophic cardiomyopathy. Presented at: 67th Biophysical Society Annual Meeting [Poster B413]; February 18\u201322, 2023; San Diego, CA, USA."},{"key":"1694_CR16","unstructured":"Grillo MP, Zamora J, Sukhun R, Morgan BP. Preclinical pharmacokinetics of CK-4021586, a novel inhibitor of cardiac myosin, and prediction of human pharmacokinetics. Presented at: American Association of Pharmaceutical Scientists [Poster 35]; October 22\u201325, 2023; Orlando, FL, USA."},{"key":"1694_CR17","doi-asserted-by":"crossref","unstructured":"Grillo MP, Zamora J, Easterday A, Azimi M, Romond R, Morgan BP, et al. In vitro and in vivo preclinical pharmacokinetic characterization of ulacamten, a small molecule cardiac myosin inhibitor for the treatment of heart failure with preserved ejection fraction (HFpEF). Xenobiotica. 2026;56(5):365\u2013 80","DOI":"10.1080\/00498254.2026.2668393"},{"issue":"1","key":"1694_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","volume":"28","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1\u201339.","journal-title":"J Am Soc Echocardiogr"},{"issue":"8","key":"1694_CR19","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jacbts.2022.04.008","volume":"7","author":"FI Malik","year":"2022","unstructured":"Malik FI, Robertson LA, Armas DR, Robbie EP, Osmukhina A, Xu D, et al. A phase 1 dose-escalation study of the cardiac myosin inhibitor aficamten in healthy participants. JACC Basic Transl Sci. 2022;7(8):763\u201375.","journal-title":"JACC Basic Transl Sci"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01694-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01694-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01694-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:19:58Z","timestamp":1790684398000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01694-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,30]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1694"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01694-6","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,30]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are employees of and shareholders in Cytokinetics, Inc.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials and can also be obtained from the corresponding author upon reasonable request. This study was conducted in compliance with the ethical principles set forth in the Declaration of Helsinki and the International Council for Harmonisation Good Clinical Practice (ICH GCP) and was registered at ClinicalTrials.gov.","order":2,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}